Mosaic Immunoengineering FY25 net loss narrows to $687,846; R&D expense drops to $64,000

• Mosaic ImmunoEngineering posted a net loss of USD 687,846 for fiscal year 2025.
• Other income from advisory services under a Master Services Agreement with Oncotelic fell to USD 14,000 from USD 42,000.
• Research and development expenses declined to about USD 64,000, while general and administrative expenses dropped to about USD 552,000.
• Cash and cash equivalents totaled about USD 4,000 as of Dec. 31, 2025, with net cash used in operating activities of USD 111,397.
• Management expects cash on hand will not satisfy operational and capital requirements through 12 months from the filing date of the annual report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mosaic Immunoengineering Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-002977), on April 15, 2026, and is solely responsible for the information contained therein.